23andMe's announcement earlier this month that it had teamed up with Pfizer in inflammatory bowel disease (IBD) could pave the way for the expansion of personalized medicine into a new area.
23andMe's announcement earlier this month that it had teamed up with Pfizer in inflammatory bowel disease (IBD) could pave the way for the expansion of personalized medicine into a new area.
So far, the personalized approach has mainly been used in cancer to identify patients with certain genetic mutations who are...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
